Standout Papers

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study 2022 2026 2023 2024126
  1. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study (2022)
    William J. Sandborn, Geert D’Haens et al. Gastroenterology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 63 standout
Sub-graph 1 of 21

Citing Papers

Fibrosis in IBD: from pathogenesis to therapeutic targets
2024 Standout
Cell death
2024 Standout
3 intermediate papers

Works of Kathleen Weisel being referenced

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
2022 Standout
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
2017
and 1 more

Author Peers

Author Last Decade Papers Cites
Kathleen Weisel 190 136 5 186 12 396
W.E. Pullman 155 147 19 79 12 373
Tuba Turul 195 62 21 171 13 398
Sarah Sague 161 144 19 90 10 398
Madeline J. Price 249 46 11 202 15 387
Melissa S. DeRycke 126 74 19 161 14 433
Luying Pan 168 86 3 182 10 369
Jun Matsuzawa 101 98 2 159 10 371
Benjamin B. Mull 89 131 9 173 12 409
Angela Giorgini 246 66 10 112 15 417
P Billing 246 75 7 137 8 443

All Works

Loading papers...

Rankless by CCL
2026